{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '6.2', 'reparation/Handling/Storage/Accountability', 'TMB-001 ointment and Vehicle ointment are manufactured in a current Good Manufacturing', 'Practice (GMP)-compliant facility and tested prior to release to ensure that the quality', 'characteristics of each clinical batch are met. TMB-001 ointment and Vehicle ointment are', 'packaged in aluminum tubes and should be stored at the conditions specified on the label as', 'follows:', 'Store at 36\u00b0F to 46\u00b0F (2\u00b0C to 8\u00b0C) until dispensed. Once dispensed, store at 68\u00b0F to 77\u00b0F', '(20\u00b0C to 25\u00b0C), excursions permitted to 59\u00b0F to 86\u00b0F (15\u00b0C to 30\u00b0C).', 'For Subjects that will be seen in clinic for Visit 2, study medication will be shipped directly to the', 'study site. The Investigator or designee must confirm that appropriate temperature conditions have', 'been maintained during transit for all study medications received and any discrepancies are', 'reported and resolved before use of the study medication.', 'For Subjects that will have Visit 2 performed remotely, the study medication will be shipped', \"directly to the subject's home. The subject will receive confirmation from the courier that\", 'appropriate temperature conditions have been maintained during transit for all study medications', 'received and the courier will report any discrepancies to the site. In case of discrepancies the site', 'will ensure they are resolved before use of the study medication and communicate that to the', 'subject.', 'Prior to using any tube, the tube must be weighed. Upon return of the tube to the study center, the', 'tube must be weighed.', 'Only subjects enrolled in the study may receive study treatment, and only authorized study center', 'staff may supply or administer study treatment. All study treatments must be stored in a secure,', 'environmentally controlled, and monitored (manual or automated) area in accordance with the', 'labeled storage conditions with access limited to the Investigator and authorized study center staff.', 'The Investigator or designee is responsible for study treatment accountability, reconciliation, and', 'record maintenance (i.e., receipt, reconciliation, and final disposition records) using the Drug', 'Accountability Form. These forms must be available for inspection at all times.', 'Further guidance and information for the final disposition of unused study medication are provided', 'in the Investigator Study Binder.', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', 'Subjects who meet all inclusion criteria and no exclusion criteria will be randomized to a treatment', 'group in a 1:1:1 ratio, stratified by CI subtype.', '29']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'All subjects will be centrally assigned to randomized study treatment using an Interactive Web', 'Response System (IWRS). Before the study is initiated, the log in information and directions for', 'the IWRS will be provided to each study center.', 'Study medication use will be accounted and dispensed at the study visits as summarized in the', 'Schedule of Activities (Section 1.2).', 'In this double-blind study, all personnel involved, ie, physicians, site staff, and participants will', 'remain blinded at all times, except in an emergency, where knowledge of the randomization code', 'is required to provide appropriate treatment. In case of an emergency, the Investigator has the sole', \"responsibility for determining if unblinding of a subject's treatment assignment is warranted.\", 'Subject safety must always be the first consideration in making such a determination. If the', 'Investigator decides that unblinding is warranted, every effort should be made to contact the', \"Sponsor and Medical Monitor prior to unblinding a subject's treatment assignment unless this\", \"could delay emergency treatment of the subject. If a subject's treatment assignment is unblinded,\", 'the Sponsor must be notified within 24 hours after breaking the blind. The date and reason that the', 'blind was broken must be recorded in the source documentation and electronic Case Report Form', '(eCRF), as applicable.', '6.4 Study Treatment Compliance', 'The prescribed dosage, timing, and mode of administration may not be changed, except as defined', 'in Section 7.4. Any departures from the intended regimen must be recorded in the eCRFs.', 'During the course of the study, compliance to study drug application will be evaluated via Subject', 'diaries and accountability by the site, including weighing the tubes. Subjects exhibiting poor', 'compliance should be counseled on the importance of good compliance to the study dosing', 'regimen.', '6.5', 'Concomitant Therapy', 'Prohibited medications include the use of the following in the Treatment Areas:', 'Topical retinoids or any other topical prescription or over-the-counter therapies that are', 'intended for, or that in the opinion of the Investigator may improve, CI within 2 weeks of', 'Visit 2 (Baseline) and until the Visit 6 (EOS);', 'Keratolytics, or topical corticosteroids within 7 days prior to Visit 2 (Baseline) and until', 'the Visit 6 (EOS); and,', 'Topical products, at Visit 2 (Baseline) and until the Visit 6 (EOS). Bland emollients and', 'over the counter low potency hydrocortisone (e.g., 1% cream) may only be used in the event', 'of severe discomfort (e.g., burning/erythema/itch) and if it is the opinion of the Investigator', 'that a drug interruption (per section 7.4) alone will not relieve the symptoms and these may', '30']\n\n###\n\n", "completion": "END"}